Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Metagenomi has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
Metagenomi's investors include RA Capital Management, HOF Capital, Catalio Capital Management, Moderna, Sozo Ventures.
Metagenomi is headquartered in Emeryville, United States.
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
Metagenomi is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Metagenomi — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/metagenomi. Accessed August 14, 2026.
VCBacked. (2023). Metagenomi — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/metagenomi
{{cite web |title=Metagenomi — Funding & Investors |url=https://www.vcbacked.co/company/metagenomi |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated